8-K: Catheter Precision Closes $3.47M Preferred Stock Sale

Catheter Precision, Inc. announced the closing of its Series C-2 Convertible Preferred Stock offering, raising $3,470,000 in gross proceeds.

Summary

• Catheter Precision, Inc. has closed a sale of its Series C-2 Convertible Preferred Stock, raising $3,470,000 in gross proceeds.
• The company also issued Series D Convertible Preferred Stock as partial consideration for the acquisition of Fly Flyte, Inc.
• The Series C-2 Preferred Stock is convertible into common stock at $0.883 per share, subject to anti-dilution adjustments and a beneficial ownership limitation of 4.99% (up to 9.99%).
• The Series D Preferred Stock is convertible at $1.1038 per share, with a similar floor price and beneficial ownership limitation.
• Proceeds from the Series C-2 offering will be used for working capital and general corporate purposes.
• Both issuances were conducted under exemptions from registration requirements, relying on Section 4(a)(2) and Rule 506(b) of the Securities Act.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it indicates capital raising and strategic acquisition activity, but also involves potential dilution and complex financing instruments.

Positives

• Successfully raised $3,470,000 in gross proceeds through the sale of Series C-2 Convertible Preferred Stock.
• Completed the acquisition of Fly Flyte, Inc. through the issuance of Series D Convertible Preferred Stock.
• Secured necessary stockholder approval for the issuance of common stock upon conversion of preferred stock.
• The conversion price for Series C-2 Preferred Stock is set at $0.883, with a floor price of $0.35.
• The conversion price for Series D Preferred Stock is set at $1.1038, with a floor price of $0.35.

Negatives

• The conversion of preferred stock into common stock will result in dilution for existing common stockholders.
• The terms of the preferred stock issuances include beneficial ownership limitations (4.99% to 9.99%), which may restrict large investors.
• The company is subject to covenants that restrict its ability to incur additional indebtedness and engage in certain transactions without holder consent.

Risks

• Potential dilution to existing common stockholders upon conversion of preferred stock.
• The company's ability to meet its obligations and covenants related to the preferred stock issuances.
• The effectiveness of the Registration Statement for resale of common stock issued upon conversion.
• The company's reliance on exemptions from registration for these equity issuances.

Future Outlook

The company intends to use the net proceeds from the Series C-2 Closing for working capital and general corporate purposes. The conversion prices for both Series C-2 and Series D preferred stock are subject to adjustments and a floor price of $0.35 per share. The conversion is also subject to beneficial ownership limitations.

Industry Context

StockSavvy.ai notes that this filing reflects common financing strategies for emerging companies in the medical device sector, utilizing convertible preferred stock to raise capital while deferring common stock dilution until conversion. The acquisition of Fly Flyte, Inc. suggests a strategy of inorganic growth to expand the company's offerings or market reach.

Corporate Governance

Related Party Transactions

• Issuance of 5,250 shares of Series D Preferred Stock to SEG Jets LLC as consideration for its transfer of common stock in Flyte.
• Issuance of 5,778 shares of Series D Preferred Stock to Creatd, Inc. as partial consideration for its transfer of common stock in Flyte.

Stakeholder Impact

• Existing common stockholders will experience dilution upon conversion of the Series C-2 and Series D Preferred Stock.
• Investors in the Series C-2 Preferred Stock gain convertible equity with specific rights and preferences.
• SEG Jets LLC and Creatd, Inc. received Series D Preferred Stock as consideration for their stake in Flyte, impacting their equity position in Catheter Precision.

Next Steps

• The company will use the proceeds from the Series C-2 offering for working capital and general corporate purposes.
• The company will manage the conversion of Series C-2 and Series D Preferred Stock into Common Stock, subject to limitations.
• The company will file a Registration Statement for the resale of common stock issuable upon conversion.

Key Dates

Recommendation

The filing details significant capital raises and an acquisition, which are positive strategic moves. However, the issuance of convertible preferred stock introduces potential dilution for common shareholders. Without further financial performance data or a clearer path to profitability, a 'hold' recommendation is prudent, allowing investors to monitor the impact of these transactions and future performance.

Keywords

Catheter Precision, 8-K, Convertible Preferred Stock, Series C-2, Series D, Equity Financing, Acquisition, Fly Flyte, Inc.